Hospital
SSM Health Care of Wisconsin, INC.
SSM Health Care of Wisconsin, INC. was paid $8.37M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoSSM HEALTH CARE OF WISCONSIN, INC.
JANESVILLE, WI 53546
JANESVILLE, WI 53546
33aNPI1194004408assigned 08/04/2011
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$8.37M
24GClaims427,044
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,767 | $786K | |
| 2019 | 56,423 | $1.10M | |
| 2020 | 54,016 | $975K | |
| 2021 | 69,979 | $1.27M | |
| 2022 | 72,164 | $1.41M | |
| 2023 | 78,169 | $1.52M | |
| 2024incomplete | 61,526 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 19,027 | 16,921 | $1.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 18,275 | 15,551 | $960K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.7% | 6,439 | 5,328 | $732K |
| 80053 | Comprehensive metabolic panel | 7.0% | 21,418 | 17,730 | $584K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 4,661 | 4,287 | $335K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.8% | 3,838 | 3,492 | $315K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 2,771 | 2,474 | $202K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 1,759 | 1,632 | $197K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 7,569 | 6,316 | $183K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 2,878 | 2,579 | $174K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 3,888 | 3,404 | $173K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 23,406 | 19,050 | $168K |
159 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 2,212 | $133K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 3,434 | $132K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 3,544 | $115K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 3,544 | $110K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 1,453 | $107K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,709 | $93K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 2,546 | $87K |
| 59025 | Fetal non-stress test | 1.0% | 1,369 | $86K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.0% | 6,234 | $85K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,279 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,884 | $81K |
| 81001 | <1% | 14,332 | $79K | |
| 81025 | <1% | 7,370 | $79K | |
| 80061 | Lipid panel | <1% | 5,518 | $78K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,695 | $78K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,077 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,395 | $68K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,178 | $66K |
| 80050 | General health panel | <1% | 3,466 | $65K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,889 | $60K |
| 85027 | <1% | 8,277 | $59K | |
| 84702 | <1% | 1,920 | $56K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 659 | $54K |
| 83655 | <1% | 1,682 | $52K | |
| 84484 | <1% | 6,468 | $51K | |
| 80306 | <1% | 2,825 | $49K | |
| 86803 | <1% | 2,366 | $47K | |
| 80143 | <1% | 1,208 | $39K | |
| 82947 | <1% | 1,493 | $38K | |
| 87081 | <1% | 1,760 | $37K | |
| 87631 | <1% | 226 | $35K | |
| 85610 | <1% | 3,455 | $35K | |
| 83690 | <1% | 6,295 | $34K | |
| 83605 | <1% | 4,448 | $34K | |
| 83880 | <1% | 1,655 | $33K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,118 | $33K |
| 84439 | <1% | 1,612 | $31K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 330 | $30K |
| 86592 | <1% | 1,695 | $29K | |
| 81003 | <1% | 5,432 | $28K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 427 | $28K |
| 87077 | <1% | 2,444 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,278 | $26K |
| 86850 | <1% | 2,796 | $26K | |
| 82962 | <1% | 3,975 | $25K | |
| G0378 | Hospital observation service, per hour | <1% | 1,424 | $24K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 341 | $24K |
| 82607 | <1% | 1,585 | $24K | |
| 87186 | <1% | 1,965 | $22K | |
| 86762 | <1% | 1,361 | $20K | |
| 82077 | <1% | 1,871 | $19K | |
| 82728 | <1% | 1,112 | $19K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 99 | $18K |
| 87210 | <1% | 2,540 | $17K | |
| 83735 | <1% | 3,160 | $16K | |
| 87340 | <1% | 1,851 | $16K | |
| 84466 | <1% | 1,429 | $15K | |
| 84145 | <1% | 964 | $14K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 263 | $14K |
| 82105 | <1% | 327 | $14K | |
| 83540 | <1% | 1,528 | $14K | |
| 80179 | <1% | 1,147 | $12K | |
| 82805 | <1% | 378 | $12K | |
| 85379 | <1% | 1,524 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 552 | $11K |
| 86140 | <1% | 1,766 | $11K | |
| 87040 | <1% | 1,433 | $9K | |
| 80076 | <1% | 659 | $8K | |
| 82746 | <1% | 585 | $7K | |
| 86900 | <1% | 2,586 | $7K | |
| 86901 | <1% | 2,632 | $6K | |
| 88142 | <1% | 335 | $6K | |
| 83021 | <1% | 116 | $5K | |
| 85652 | <1% | 1,778 | $4K | |
| 82043 | <1% | 801 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 116 | $4K |
| 82565 | <1% | 591 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,217 | $4K |
| 82570 | <1% | 846 | $4K | |
| 86780 | <1% | 346 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,253 | $3K |
| 82550 | <1% | 146 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,438 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,226 | $2K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 14 | $2K |
| 85018 | <1% | 989 | $2K | |
| 81329 | <1% | 14 | $2K | |
| 85014 | <1% | 409 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,661 | $2K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 49 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,764 | $1K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 126 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,717 | $1K |
| 86706 | <1% | 104 | $1K | |
| 86038 | <1% | 88 | $918.82 | |
| 87634 | <1% | 18 | $763.32 | |
| 84550 | <1% | 138 | $732.07 | |
| 83970 | <1% | 17 | $690.71 | |
| 82784 | <1% | 28 | $675.62 | |
| 86787 | <1% | 58 | $649.11 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,196 | $604.87 |
| 95800 | <1% | 12 | $579.12 | |
| 36591 | <1% | 65 | $523.92 | |
| 85730 | <1% | 138 | $486.93 | |
| 84156 | <1% | 41 | $477.23 | |
| 87070 | <1% | 60 | $400.64 | |
| 86364 | <1% | 27 | $371.48 | |
| 83516 | <1% | 39 | $369.68 | |
| 84703 | <1% | 14 | $333.63 | |
| 86705 | <1% | 39 | $328.46 | |
| 83525 | <1% | 43 | $309.35 | |
| 87807 | <1% | 19 | $230.32 | |
| 87205 | <1% | 73 | $199.38 | |
| 97162 | <1% | 17 | $190.44 | |
| 87147 | <1% | 29 | $155.33 | |
| 88342 | <1% | 68 | $118.59 | |
| 96376 | <1% | 1,641 | $109.51 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,293 | $34.06 |
| 73610 | <1% | 237 | $18.61 | |
| 73562 | <1% | 220 | $18.17 | |
| 88304 | <1% | 43 | $17.54 | |
| 73130 | <1% | 27 | $17.27 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,251 | $14.42 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,530 | $5.30 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,445 | $4.95 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 944 | $1.46 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,103 | $1.43 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 756 | $1.35 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 922 | $1.30 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,984 | $1.10 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,390 | $1.05 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,973 | $0.89 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,234 | $0.88 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 991 | $0.84 |
| A9270 | Non-covered item or service | <1% | 2,706 | $0.64 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,869 | $0.38 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,055 | $0.07 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,381 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 3,367 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 169 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 159 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 79 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 233 | $0.00 |
| 76801 | 0% | 19 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 19 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 13 | $0.00 |
| 72100 | 0% | 12 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 88 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 65 | $0.00 |
| 73030 | 0% | 26 | $0.00 | |
| 74018 | 0% | 55 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 32 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 37 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 46 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 51 | $0.00 |
| 73630 | 0% | 236 | $0.00 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 0% | 27 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMINERATH, JOSEPH (SYSTEM DIRECTOR GOV'T REIMBURSEMENT)
| Provider | Location | Paid |
|---|---|---|
| SSM Health Care of Wisconsin, INC. | Madison, WI | $14.70M |
| SSM Health Care of Wisconsin INC | Baraboo, WI | $9.78M |
| SSM Health Care of Wisconsin, INC | Madison, WI | $6.40M |
| Ripon Medical Center INC | Ripon, WI | $4.30M |
| Agnesian Healthcare INC | Fond Du Lac, WI | $2.25M |
| SSM Health Care of Wisconsin INC | Janesville, WI | $1.03M |
| Agnesian Healthcare INC | Fond Du Lac, WI | $172K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.